XAIR - Beyond Air - $4.96 Retest - $6.88 PTNASDAQ:XAIR had a breakout from a larger Descending Wedge that it broke out of and continued consolidation. The company's catalyst: FDA Orphan Drug Adoption for Brain Cancer Drug Candidate.
Looking for some consolidation back to that level or projected support, seeing we're not finding support, but resistance currently at the $4.35s which it's need some continued support to push up from here.
